New pill targets Hard-to-Treat cancers in early human trial
NCT ID NCT07593144
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests an experimental oral drug called FS-207 in 156 adults with advanced solid tumors that have a specific DNA repair flaw (MSI-H). The drug works by blocking a protein (WRN) that these cancer cells need to survive. The study aims to find a safe dose and check for early signs that the drug shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FS-207 (an oral drug that targets the WRN protein)
- What this could lead to
- If successful, this could lead to a new oral treatment option for people with MSI-H advanced solid tumors who have run out of standard therapies.
- What could go wrong
- This is an early Phase 1 trial, so the drug may not be safe or effective. Only a small number of patients will be tested, and results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital of Shandong First Medical School
Jinan, Shandong, 250117, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, 750004, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, 330029, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130012, China
-
Peking Union Medical College Hospital
Beijing, 100730, China
-
Peking University Cancer Hospital
Beijing, 100142, China
-
Shanghai Tenth People's Hospital
Shanghai, 200072, China
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266000, China
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
-
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, 110001, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, 430030, China
-
West China Hospital,Sichuan University
Chengdu, Sichuan, 610041, China
-
the Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.